warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'ctools_menu_help' not found or invalid function name in /var/www/ on line 669.


Professeur André J. SCHEEN, Université de Liège, Belgique
Unité de Pharmacologie Clinique (ATC) – C.H.U. Liège




Pharmacocinétique clinique

Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Metab Obes, 2010, 12, 648-658.


Interactions médicamenteuses et alimentaires

Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents : an update. Drug Safety, 2005, 28, 601-631.

Scheen AJ. Diabetes, obesity, and metabolic syndrome. In : Nutrient-drug interactions (Ed : Meckling KA), CRC Press Taylor & Francis, Boca Raton, FL, US, 2007, 1-30.

Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet, 2007, 46, 1-12.

Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet, 2007, 46, 93-108.

Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins) : Focus on drug-drug interactions. Clin Pharmacokinet, 2010, 49, 573-588.

Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Exp Opin Drug Metab Toxicol, 2011, Aug 2. [Epub ahead of print]


Thérapie combinée synergétique

Radermecker RP, Scheen AJ. Serum plant sterols and atherosclerosis : is there a place for statin-ezetimibe combination ? (Letter). J Am Coll Cardiol, 2006, 47, 1496-1497.

Legrand D, Krzesisnki JM, Scheen AJ. Quelle place pour une double ou triple inhibition du système rénine-angiotensine-aldostérone. Rev Med Suisse, 2008, 4, 1792-1797.

Scheen AJ et al. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabetic Med, 2009, 26, 1033-1039.

Scheen AJ et al. Long-term glycaemic effects of pioglitazone versus placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabetic Med, 2009, 26, 1242-1249.

Charbonnel B et al. Pioglitazone use in combination with insulin in the prospective Pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab, 2010, 95, 2163-2171.

Scheen AJ et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2010, 26, 540-549.

Scheen AJ, Radermecker RP.  Addition of incretin therapy to metformin in type 2 diabetes (Comment). Lancet 2010, 375, 1410-1412.

Scheen AJ. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opin Drug Metab Toxicol, 2010, 6, 1265-76.


Efficacité clinique

Philips JC, Scheen AJ. Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag, 2006, 2, 277-283.

Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus (Letter). Eur Heart J, 2006, 27, 2900.

Scheen AJ, Paquot N. Pharmacological treatment of obesity, food intake, and reversal of metabolic disorders. Curr Nutr Food Sci, 2007, 3, 123-133.

Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion DJr, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Gallois Y, Amouyel P, Ollivier JP, Asmar R. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens, 2007, 20, 90-97.

Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes : a randomised controlled study. Lancet, 2006, 368, 1660-72.

Scheen AJ. Does the metabolic syndrome help select patients requiring high statin dose ? (Editorial).  Lancet, 2006, 368, 893-4.

Scheen AJ. Antidiabetic agents in patients with mild dysglycaemia : prevention or early treatment of type 2 diabetes ? Diabetes Metab, 2007, 33, 3-12.

Scheen AJ. Exenatide once weekly in type 2 diabetes (comment). Lancet, 2008, 372, 1197-1198.

Scheen AJ. Pharmacological prevention of type 2 diabetes. In : The Epidemiology of Diabetes Mellitus. (Eds: J-M Ekoe, M Rewers, R Williams, P Zimmet), Wiley-Blackwell London, UK, 2008, Chapter 29, pages 449-474.

Ruilope LM, Després JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities : analysis of pooled RIO study results. J Hypertension, 2008, 26, 357-367.

Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients : pooled 1-year data from the rimonabant in obesity (RIO) program. Diabetes Care, 2008, 31 (Suppl. 2), S229-S240.

Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors : overview of the RIO programme with rimonabant. J Neuroendocrinol, 2008, 20 (Suppl. 1), 139-146.

Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O. RIO-Europe Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors : 2-year results from the RIO-Europe Study. Eur Heart J, 2008, 29, 1761-1771.

Scheen AJ. The future of obesity : new drugs versus lifestyle interventions? (Editorial). Exp Opin Invest Drugs, 2008, 17, 263-267.

Scheen AJ, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care, 2008, 11, 505-511.

Scheen AJ. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab, 2009, 23, 103-116.

Scheen AJ. The endocannabinoid system : a promising target for the management of type 2 diabetes. Curr Protein Pept Sci, 2009, 10, 56-74.

Annemans L, Marbaix S, Webb K, Van Gaal L, Scheen A. Cost-effectiveness of atorvastatin in type 2 diabetes patients : a pharmaco-economic analysis of the - Collaborative Atorvastatin Diabetes Study (CARDS) in the Belgian population. Clin Drug Investig, 2010, 30, 133-142.

Beck E, Scheen AJ. Activité anticancéreuse de la metformine : nouvelles perspectives pour une vieille molécule. Rev Med Suisse, 2010, 6, 1601-1607.

Scheen AJ, Radermecker RP, Ernest P, Jandrain B. Inhibiteurs du cotransporteur du glucose SGLT2 rénal pour traiter le diabète de type 2.  Rev Med Suisse, 2011, 7, sous presse.

Esser N, Paquot N, Scheen AJ. Diabète de type 2 et médicaments anti-inflammatoires : nouvelles perspectives thérapeutiques ? Rev Med Suisse, 2011, 7, sous presse.

Scheen AJ.  Linagliptin for the treatment of Type 2 diabetes (Pharmacokinetic Evaluation). Expert Opinion on Drug Metabolism and Toxicology, 2011, in press.


Profil de toxicité du médicament

De Flines J, Scheen AJ. Glitazones et insuffisance cardiaque : résultats des études PROactive, ADOPT, DREAM et RECORD. Rev Med Suisse, 2007, 3, 1876-1883.

Van Gaal LF, Scheen AJ, Formiguera X. The safety of obesity drugs. Exp Opin Drug Saf, 2007, 6, 475-476.

Scheen AJ, De Hert M. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab, 2007, 33, 169-75.

Scheen AJ. Medications in kidney. Acta Clin Belg, 2008, 63, 76-80.

Scheen AJ. Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death? Nat Clin Pract Endocrinol Metab, 2008, 4, 260-261.

Scheen AJ. Controversy about the cardiovascular safety of sibutramine. Drug Safety, 2010, 33, 615-618.

Scheen AJ. Sibutramine : a review of its cardiovascular risk-benefit profile. Am J Cardiovasc Drugs, 2010, 10, 321-334.

Scheen AJ. Sibutramine on cardiovascular outcome. Diabetes Care, 2011, 34 (Suppl 2), S114-119.


Etudes sur les résultats cardiovasculaires

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet, 2005, 366, 1279-1289.

NAVIGATOR : Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010, 362, 1463-76.

NAVIGATOR : Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010, 362, 1477-1490.

SCOUT : Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med, 2010, 363, 905-917.

CRESCENDO : Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, 2010, 376, 517-523.

Delanaye P, Scheen AJ. Effects of fibrates on cardiovascular outcomes (Letter). Lancet, 2010, 376, 1051.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.  - - Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med, 2011, 10, 364, 907-917.


Publications générales en pharmacologie clinique

Scheen AJ. Interactions médicamenteuses: de la théorie à la pratique. Rev Med Liège, 2006, 61, 471-482.Scheen AJ, Parada A, Giet D. Conseils pour une meilleure prescription médicamenteuse. Rev Med Liège, 2006 ,61, 488-493.

Scheen AJ. Editorial. A propos de la plus-value thérapeutique. Rev Med Liège, 2007, 62, 241-243.

Scheen AJ, Giet D. Cibler l'inertie et le défaut d'observance thérapeutiques : nouveau défi pour améliorer les performances de la pratique médicale. Rev Med Liège, 2010, 65, 229-231.

Scheen AJ, Giet D. Non-observance thérapeutique: causes, conséquences, solutions. Rev Med Liège, 2010, 65, 239-45.

Jandrain BJ, Ernest P, Radermecker RP, Scheen AJ. Stratégies pour éviter l'inertie et la non-observance dans les essais cliniques. Rev Med Liège, 2010, 65, 246-249.

Scheen AJ, Lefèbvre PJ, Kulbertus H. Prévention cardio-vasculaire : la "polypill", une solution pour vaincre l'inertie clinique et le manque d'observance ? Rev Med Liège, 2010, 65, 267-272.